#USA #Orlando #HAE #Argo Biopharma #BW-20805

Argo Biopharma's Phase I Study Results for BW-20805

In a significant development for patients suffering from Hereditary Angioedema (HAE), Argo Biopharmaceutical Co., Ltd. has announced that it will present positive findings from its Phase I clinical trial of the investigational therapeutic, BW-20805, at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. This event is set to take place from November 6 to 10, 2025, in Orlando, Florida.

Overview of BW-20805

BW-20805 is an innovative small interfering RNA (siRNA) therapy aimed at targeting prekallikrein (PKK), a key player in the pathophysiology of HAE. Traditionally, patients with this rare genetic condition have faced daunting challenges, with a mortality risk potentially as high as 40% due to severe episodes where uncontrolled swelling can obstruct the airway. The advent of BW-20805 opens up the possibility of significantly reducing the frequency and severity of these attacks, heralding a new era in HAE management.

Positive Clinical Data

During the ACAAI meeting, the poster presentation is titled "Hereditary Angioedema Prophylaxis With Prekallikrein siRNA-Phase I Safety Outcomes And Prekallikrein Levels" (Poster ID R094). The data showcases that BW-20805 was well tolerated across all evaluated dose ranges from 50 to 600 mg. Notably, there was no dose-dependent increase in treatment-emergent adverse events, and no cases of serious adverse events or discontinuities related to the drug were reported. This speaks volumes about the safety of the treatment.

One of the hallmark findings from the trial indicated that treatment with BW-20805 resulted in rapid and significant reductions in plasma PKK levels. Specifically, reductions peaked at 75% for the 50 mg dosage, escalating to 95% for the 600 mg dosage. Importantly, the effects of the treatment were sustained for up to 24 weeks, suggesting that patients may benefit from even longer dosing intervals of up to six months.

Further reinforcing the therapeutic action of BW-20805, additional biomarkers such as plasma proenzyme activation and cleaved high-molecular-weight kininogen showed significant decreases throughout the study.

Expert Commentary

Dr. Dongxu Shu, co-founder and CEO of Argo Biopharma, commented on the exciting Phase I results, stating, "We are pleased with the results shared at ACAAI, showing that BW-20805 was well tolerated across all dose levels, with rapid, profound, and durable reductions in plasma PKK levels achieved. We look forward to further advancing BW-20805 as a potential long-acting and effective therapy for people living with HAE.”

The Significance of BW-20805

Hereditary angioedema impacts approximately 1.5 people per 100,000 globally and presents unique challenges due to its unpredictable nature. Current therapies often require patients to maintain frequent dosing, highlighting a significant gap for long-acting preventive treatments. BW-20805’s innovative approach to directly target and inhibit the PKK mRNA offers an exciting pathway for those affected by HAE, promising a future where patients can live with less fear of sudden attacks.

About Argo Biopharma

Headquartered in Shanghai and Boston, Argo Biopharma is a clinical-stage biotechnology firm focused on the development of next-generation RNA interference therapeutics. With a diversified pipeline that targets a wide array of conditions such as cardiovascular issues, viral infections, and various rare diseases, the company demonstrates a robust commitment to improving therapeutic landscape across multiple domains.

For more detailed information, visit Argo Biopharma's website.

In conclusion, the promising results from Argo Biopharma's Phase I clinical trial highlight a significant step forward in the treatment of HAE. With further development and clinical validation of BW-20805, there is substantial hope for enhanced management of this previously challenging condition.